Primary ALK-negative anaplastic large cell lymphoma with extensive bone involvement mimicking multiple myeloma and metastatic carcinoma
Authors:
João Tadeu Damian Souto Filho, Rodrigo Aires de Morais, Ana Laura Oliveira Silveira, Arthur Pires Lacerda, Arthur Zopé Pires, Helena Alves de Andrade Ribeiro, Isabela Peçanha Bogado Fassbender, João Marcos Marcelino Chaves Ribeiro, Luiz Coelho Soares Figueiredo, Luiza Reis de Sales, Wellington dos Santos Ferreira Júnior, Yasmim Passos Dias
A 68-year-old woman presented with a 4-month history of intense and diffuse bone pain, weight loss, and night sweats. Initially, the pain was localized in the right iliac and sacral region, but later it spread to both arms and legs. Physical examination revealed no lymphadenopathy or hepatosplenomegaly. Laboratory tests showed anemia (hemoglobin 8.5 g/dL), leukocytosis (13 × 109/L) with neutrophilia (9 × 109/L), elevated C-reactive protein (68.5 mg/L) and erythrocyte sedimentation rate (127 mm/hr). Other results, including platelets, lactate dehydrogenase, calcium, uric acid, serum protein electrophoresis, immunofixation for monoclonal proteins, and renal, liver, thyroid and parathyroid function testes, were normal. 18-Fluorodeoxyglucose positron emission tomography/computed tomography scanning (18F-FDG PET/CT, Fig. 1a) showed increased FDG uptake in multiple bone osteolytic lesions with cortical permeation-associated soft tissue components localized in right radio and humerus, right ilium and sacral wing (SUVmax 11.3, Fig. 1b), right and left femur (SUVmax 12.5, Fig. 1c) and proximal third of right fibula.
Primary ALK-negative anaplastic large cell lymphoma with extensive bone involvement mimicking multiple myeloma and metastatic carcinoma
Authors
João Tadeu Damian Souto Filho Rodrigo Aires de Morais Ana Laura Oliveira Silveira Arthur Pires Lacerda Arthur Zopé Pires Helena Alves de Andrade Ribeiro Isabela Peçanha Bogado Fassbender João Marcos Marcelino Chaves Ribeiro Luiz Coelho Soares Figueiredo Luiza Reis de Sales Wellington dos Santos Ferreira Júnior Yasmim Passos Dias
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.